Anticoagulated patient’s perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy – study protocol for The Switching Study: a prospective cohort study

Vivian Auyeung2*, Jignesh P. Patel1,2, John K. Abdou1,2, Bipin Vadher1, Lynda Bonner1, Alison Brown1, Lara N. Roberts1, Raj K. Patel1 and Roopen Arya1

Abstract

Background: Anticoagulant therapy is prescribed for millions of patients worldwide for the prevention and treatment of both arterial and venous thrombosis. Historically, only vitamin K antagonists have been available for clinicians to prescribe. The anticoagulation landscape is changing. The recent availability of the novel oral anticoagulants overcome many of the disadvantages associated with vitamin K antagonists. However the lack of formal monitoring and clinic follow-up is a concern for clinicians, as medication adherence is being assumed, which is known to decline in patients prescribed medications for chronic conditions. The switching study is a programme of work investigating the association between medication adherence and patient’s beliefs about anticoagulation therapy (warfarin and subsequently novel oral anticoagulants), together with beliefs about their illness and anticoagulation related quality of life.

Methods/design: The anticoagulation database at King’s College Hospital will be interrogated and two groups of patients will be identified; those with a time in therapeutic range on warfarin of ≥75 % and those <50 %. These groups of patients will have their illness perceptions, anticoagulation specific quality of life and beliefs about medications compared. Those patients in the time in therapeutic range <50 % group, will be then be invited to switch to a novel oral anticoagulant, as per local guidance. Those patients, who do switch, will then be followed longitudinally and have their adherence, illness perceptions, anticoagulation specific quality of life and beliefs about medications, re-evaluated on the novel agent. The results from these sub-studies, will inform a clinical pathway to support patients on these novel agents, which will be evaluated in an independent group of patients.

Discussion: The results from the switching study will be used to develop a clinical pathway to support patient’s prescribed novel oral anticoagulant therapy long-term.

Keywords: Anticoagulants, Atrial fibrillation, Beliefs, Illness perceptions, Medication adherence, Venous thromboembolism, Quality of life

* Correspondence: vivian.auyeung@kcl.ac.uk

1Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King’s College London, 5th Floor, Franklin-Wilkins Building, London SE1 9NH, UK

Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Anticoagulant therapy is prescribed for millions of patient’s world-wide, most commonly for the acute treatment and long-term prevention of venous thromboembolism (VTE) and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1, 2]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1, 2]. VKA therapy comes with some practical disadvantages; need for monitoring and a relatively significant number of drug-drug and drug-food interactions, which has meant that not all patients eligible have benefitted from these agents in the past [3]. In recent years, the aforementioned disadvantages has led to the development of new classes of oral anticoagulants, the direct thrombin inhibitor (dabigatran) and the direct Xa inhibitors (apixaban, betrixaban, edoxaban, rivaroxaban). These agents hold many advantages over VKA, primarily of a predictable pharmacokinetic nature, meaning that there is minimal requirement for regular monitoring of anticoagulant effect [4]. In the United Kingdom (UK), the available direct oral anticoagu- lants, apixaban, dabigatran, edoxaban and rivaroxaban are all approved for AF and VTE indications and available for clinicians to prescribe as treatment options, when clinically indicated [5–13]. Indeed their availability has sparked local initiatives to ensure that patients in AF with a CHA2DS2-VASc score [14] of two or above are offered oral anticoagu- lation, be it with VKA or the novel agents, referred to herein as NOAC. The general perception is, that the NOACs are easier to use, so uptake both from a clinician (prescribing) and patient (receiving) perspective is likely to be higher, with cost analyses modelling suggesting that these agents are cost-effective [5–13]. Treatment pathways across the UK are being revisited to accommodate these agents and the advantages they bring. However, these agents are not free from risks. Compared to VKA, little experience exists on how these agents perform long-term, e.g. in minimising complications associated with VTE such as the post-thrombotic syndrome. Additionally, there are currently no antidotes available for the direct Xa inhibitors; a situation which is likely to change in the coming months. Finally, the benefits cited for the NOACs assume that patients actually take the medication as prescribed. Research suggests that approximately 30–50 % of medication prescribed for chronic conditions are not taken as intended [15]; adherence is often found to be high during the initial months of therapy and then found to decline in many patients [16], with clinician’s ability to recognise medication non-adherence reported to be poor [17–20]. Medication non-adherence not only impacts negatively on the patient concerned, the wider health-care economy is adversely affected [21]. Research confirms that individual patient’s beliefs about medicines are a strong predictor of their adherence to treatment. These beliefs can be grouped under two categories; (1) perceptions of necessity and (2) concerns about negative effects [22]. Therefore beliefs that failure to take the treatment could result in adverse consequences is associated with higher adherence rates (and vice versa). Acknowledging that all patients will have differing beliefs about their medications is the first step in addressing the medication non-adherence problem [22, 23].

With the availability of NOAC therapy, an opportunity now exists to re-visit patients who are currently prescribed VKA with poor anticoagulation control, and consider switching their anticoagulant therapy to a NOAC. The question is how to determine success or failure on VKA. A common method of determining good anticoagulation control on VKA is through their time in therapeutic range (TTR). The Rosendaal method [24] is the most widely used method to calculate TTR and uses linear interpolation to calculate an INR value for each day between observed INR values (over a 1 year period). The TTR represents the percentage of these INR values in days that are in the therapeutic range. The TTR is a valid marker to use in clinic, as it has been reported to predict clinical outcomes such as major bleeding, stroke and systemic embolic events [25]. TTR provides a means, however imperfect [26], of identifying possible medication non-adherence and/or whether the patient may benefit from a switch to NOAC. In the UK, national guidelines suggest using the TTR criteria for determining which patients might be prioritised for switching to a NOAC. Indeed, the recently published National Institute for Care Excellence guidelines for AF stipulate that anticoagulation clinics should reassess anticoagulation for patients with poor anticoagulation control, and one of the criterion specified for re-assessment is if a patient’s TTR is <6 % [27].

Non-adherence in the context of anticoagulant therapy is not new and the issue has received attention from researchers in the past [28–32], with the importance of non-adherence to NOAC now emerging [33–35]. Little research exists on what patients general and specific concerns or necessity might be about the VKA that they are currently prescribed. This is important, as with a significant change in the anticoagulation landscape, understanding the patient perspective, particularly those with poor TTR, could help identify patterns of concerns that this group of patients may have, which could impact on their medication taking behaviour, if switched to a NOAC. Studying this would help with service delivery and determine if a specific clinical pathway would support adherence with chronic anticoagulant therapy in those identified or suspected of poor adherence - as currently, no long term pathway for NOAC patients is expected to be in place.

The Switching study is a series of prospective studies designed to investigate the association between medication
adherence and patients’ beliefs about anticoagulation therapy (warfarin and subsequently NOAC) together with beliefs about their illness and anticoagulation-related quality of life.

The Switching study aims to test the following hypotheses:

Patients’ beliefs about warfarin and their illness perceptions is associated with their adherence to warfarin as measured by time in treatment range (TTR), over and above any clinical or demographic variables.

Patients’ beliefs about NOAC at baseline and their illness perception can predict their adherence to NOAC, over and above any clinical or demographic variables.

Patients with symptomatic disease (either VTE or AF) have higher necessity scores for anticoagulant treatment compared to patients with asymptomatic disease.

Patients with a TTR >75 % have low concerns and higher necessity scores for warfarin than those with a TTR <50 %.

Patient’s responses to the illness perception questionnaire (IPQ) is specific to treatment and will change, following a switch to NOAC.

Patient’s quality of life scores improve following a switch to NOAC.

Methods/design

Patients and patient selection

Anticoagulated patients who meet the inclusion criteria, defined by their TTR, will be identified through the DAWN® databases used at King’s College Hospital NHS Foundation Trust. King’s College Hospital is a large teaching hospital, based in South East London, providing specialist tertiary services of liver disease and transplantation, neurosciences, haemato-oncology, cardiology and foetal medicine. The anticoagulation service at King’s is provided between two hospital sites; Denmark Hill and Bromley. The combined anticoagulation population is ~6, 000 patients, with a clinic average TTR of 76 and 73 % for the Denmark Hill and Bromley sites respectively.

Patient selection for the studies will be dictated by their current time TTR, as per protocol and whether patients fit the eligibility criteria. The anticoagulant clinic at King’s utilises the DAWN® software, and the TTR is calculated for patient’s prescribed chronic anticoagulation, by reviewing INR values 1 year from the date of calculation. The TTR calculation utilises the Rosendaal method [24].

Psychometric instruments

The instruments which will be administered to patients in this study comprise of the Beliefs about Medicines Questionnaire (BMQ) [36], the revised Illness Perception Questionnaire (IPQ-R) [37] and the Anti-Clot Treatment Scale (ACTS) [38] quality of life instrument. The BMQ is a validated instrument for assessing patient’s beliefs about medicines in general (overuse and harm) and their prescribed medication specifically (necessity and concerns). The IPQ-R is a validated instrument that assesses patient’s perception of their illness. The measures identity - the symptoms the patient associates with the illness, cause - personal ideas about aetiology, time-line - the perceived duration of the illness (chronicity) and how it fluctuates (cyclical), consequences - expected effects and outcome and cure control - how one controls or recovers from the illness (personal control) and the treatments available to manage it (treatment control). There is also a global measure of illness coherence – the degree to which the illness makes sense to the patient and emotional representation - a measure of the impact of the illness on their emotional well-being. The ACTS is a 17-item anticoagulation specific quality of life instrument which measures burden (a 12-item scale) and benefits (a 3-item scale). The questionnaire packs administered to patients in the Switching study are available as Additional files 1, 2, 3 and 4 with this manuscript.

Switching study series

Study I

For study I, two groups of patients prescribed chronic VKA for the primary and secondary prevention of stroke in the context of AF and for treatment and secondary prevention of VTE, will be recruited: those with a TTR >75 % (group 1) and those with a TTR <50 % (group 2). The TTR cut-off’s of >75 and <50 % were chosen to inform groups 1 and 2, based on the availability of the NOACs providing an opportunity to switch patients poorly controlled on VKA; it was felt that the patients with the poorest control should be given this option to switch first, i.e. be prioritised. Furthermore, having two distinct groups (<50 and >75 %) and understanding and appreciating the differences between these two groups will ensure that the hypotheses posed could be tested and if appropriate, a suitable support mechanism can be developed for patients prescribed chronic NOAC therapy where it is anticipated that adherence might be an issue.

For group 1 patients, their illness perception for why they are prescribed anticoagulant therapy, their beliefs about VKA and their anticoagulation specific quality of life explored through the aforementioned psychometric instruments [36–38], once through the post. Eligible patients will be consecutively identified from the DAWN® database. These patients will remain on VKA therapy, due to their excellent TTR.

In contrast, group 2 patients, due to their poor TTR will specifically be invited to clinic (visit 1) to have their
beliefs about warfarin, their perception of their illness and their quality of life explored through the aforementioned validated instruments. Study I will assess the association between adherence to warfarin and i) patient beliefs about treatment and ii) patient perception of their illness and compare responses from group 1 and group 2 patients. In addition, a baseline level for patient's anticoagulation-specific quality of life will be established.

Study II
Following completion of the psychometric instruments, patients in group 2 (from study I) will be asked if they wish to switch to a NOAC, according to local guidelines. Patients who then switch will prospectively be followed in clinic will be required to return for a clinic visit at 1, 2 months and 1 year into NOAC treatment allowing for the longitudinal assessment of adherence. At their 1-month follow-up visit (visit 2), patients will be given a questionnaire pack comprising of validated instruments designed to assess their newly established beliefs about NOAC therapy and any short-term changes in quality of life. The same instruments will be administered at their 1-year follow-up (visit 4) to determine whether any changes in beliefs, illness perceptions and quality of life are sustained. The questionnaire pack will be posted to the patient, prior to their clinic visit 4, requesting them to complete and bring along to their clinic appointment.

To prevent participant burden, no questionnaires will be administered at the 2-month follow-up visit (visit 3). However, at 1-month and 2-month follow-up visits (visits 2 and 3), patients will be asked to bring in their NOAC medication to clinic, so a pill count can be conducted by the reviewing clinician. Patients identified in this group who decline a switch to a novel agent, will also be followed longitudinally for the duration of the study and any clinically relevant outcomes will be reported. Furthermore, their reasons for not wishing to switch, will formally be recorded and described.

Analysis for studies I and II will be conducted on an intention to treat basis.

Study III
Following completion of studies I and II, the data collected will be analysed and used to design a clinical pathway which will be evaluated in a third (independent) group of patients (group 3 – patients with a TTR <50 %). The clinical pathway will be informed from the 2-month follow-up data collected up to visit 3 from patients in group 2 of study II. Group 3 patients will have the same follow-up in clinic as per the schedule outlined for group 2 patients, and analysis for study III will also be conducted on an intention to treat basis. The findings from group 2 patients (beliefs about medicines, illness perceptions, quality of life and adherence to anticoagulant therapy) will then be compared to the findings from group 3 patients. In this way, this controlled study design will then allow an assessment of the effectiveness of the clinical pathway developed. Figure 1 summarises the three studies which form this programme of work.

Inclusion criteria
All patients with a TTR <50 % prescribed warfarin therapy (for recruitment to group 2 and group 3). Where the low TTR is not due recent hospital admissions, surgical procedures or significant drug changes; this will be determined, following initial identification of patients in this group.

A control group will also be recruited comprising of patients with a TTR >75 % (for recruitment to group 1).

Exclusion criteria
Patients with a TTR >50–<75 % (for recruitment to group 2 and group 3).

Patients with a contra-indication to NOAC (i.e. abnormal liver function tests, CrCl <15 ml/min, taking concurrent interacting drugs which are contra-indicated).

Those patients unable to attend clinic for a formal consultation.

Those patients unable to read English.

Those patients who do not wish to participate.

Pregnant patients.

Study outcomes
- Individual % medication adherence to direct acting anticoagulant therapy (1 year following switch)
- Changes in patients beliefs about the anticoagulation therapy prescribed, at 1 month and 1 year following a switch to NOAC therapy
- Changes in patients illness perceptions (1 month and 1 year following switch)
- Changes in patients anticoagulation specific quality of life (1 month and 1 year following switch)
- Persistence with NOAC therapy, following a switch from VKA (1 year following switch)

Data collection
Table 1 outlines the study visit schedule and what instruments will be administered when for study II, including details of clinical information collected for patients who consent to the study. For study III, a new group of patients will be recruited, with the study visit schedule also following the schedule outlined in Table 1.

For studies II and III, patients will be reviewed by pharmacists trained in the field of anticoagulation working at King’s College Hospital. The questionnaire will be administered by the pharmacist reviewing the patient in
clinical, with patients offered the option of completing the questionnaire in clinic or taking home and returning at their subsequent clinic visit. Patients will be advised that the questionnaires will take approximately 20 min to complete.

Patients who are prescribed long-term anticoagulation for the secondary prevention of VTE, and whose primary VTE event was a deep vein thrombosis, will at each clinic visit, have an assessment of post-thrombotic syndrome (PTS) using the Villalta score [39], as part of their clinical review at clinic visits.

Adherence to NOAC
During the first 2 months of therapy, adherence to NOAC will be recorded through a pill count at the 1 and 2 month follow-up visits (visits 2 and 3). This pill count will be conducted by the pharmacist reviewing the patient in clinic and will compare the number of tablets the patient has to the number of tablets the patient is expected to have, following the commencement of NOAC. When patients are reviewed in clinic at 1 year into their NOAC therapy, specific adherence screening questions will be asked to assess adherence during

Table 1 Schedule of visits for patients recruited to studies II and III

<table>
<thead>
<tr>
<th>Visit 1 (baseline – on VKA)</th>
<th>Visit 2 (1 month into NOAC)</th>
<th>Visit 3 (2 months into NOAC)</th>
<th>Visit 4 (1 year into NOAC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full medical and drug history obtained, including calculation of CHADS2 [44], CHA2DS2-VASC [14], HASBLED [45], the Medication Related Complexity Index (MRCI) [46], SAmT-TT/R [26], the Charlson index [47] and whether the patient has symptomatic disease or not</td>
<td>Patient reviewed clinically</td>
<td>Patient reviewed clinically</td>
<td>IPQ/BMQ (NOAC)/ACTS instruments administered</td>
</tr>
<tr>
<td>Socio-demographic information&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Patient self-reported missed doses recorded + pill count</td>
<td>Patient self-reported missed doses recorded + pill count</td>
<td>PTS assessment if DVT patient</td>
</tr>
<tr>
<td>Informed written consent</td>
<td>Another 1 month prescription of NOAC given to patient</td>
<td>Another 1 month prescription of NOAC given to patient</td>
<td>Adherence assessment through GP summary care record, patient self-report and the 8-item Morisky Medication Adherence Scale</td>
</tr>
<tr>
<td>IPQ/BMQ (warfarin)/ACTS instruments administered</td>
<td>Bloods for UEs/FBC</td>
<td>Bloods for UEs/FBC (if not done at visit 2)</td>
<td></td>
</tr>
<tr>
<td>Patient switched to NOAC (1 month prescription)</td>
<td>IPQ/BMQ (NOAC)/ACTS instruments administered</td>
<td>Patient transferred to GP for on-going prescriptions</td>
<td></td>
</tr>
<tr>
<td>PTS assessment if DVT patient</td>
<td>PTS assessment if DVT patient</td>
<td>PTS assessment if DVT patient</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>only for patients prescribed anticoagulant therapy in the context of atrial fibrillation
<sup>b</sup>socio-demographic information will be obtained from the patient’s medical notes, namely age, gender, postcode, ethnicity
months 4 to 12 of NOAC therapy [40] in addition to 
asking patients how many doses of their anticoagulation 
they have missed during the last week. The adherence 
screening questions at this visit are informed from the 
8-item Morisky Medication Adherence Scale [41]. Fur-
thermore, in order to assess persistence with their anti-
coagulation therapy, patient’s summary care record and 
prescriptions records will be reviewed, allowing antico-
gulation coverage to be calculated, during the period 
which the GP was prescribing the NOAC for the patient, 
in order to measure persistence up to this time point.

Consent, confidentiality and data storage
Group 1 patients will be sent the study patient informa-
tion leaflet, along with the study questionnaire and a 
pre-paid envelope, to return the completed question-
naire to the research team.

When group 2 patients are invited for the consultation 
in the anticoagulation clinic, they will be sent the study patient information and asked to read it prior to their 
clinic visit. At the clinic visit, the pharmacist in clinic 
will ask the patient if they wish to participate in the 
study and address any questions they may have. For 
those patients who indicate that they interested, the 
pharmacist will recruit them into the study. Informed 
written consent will be taken by the pharmacist. For 
those patients who do not wish to participate, the 
pharmacist will still offer the patient the opportunity to 
switch to a NOAC, as per local guidance.

A similar process to that of group 2 patients will be 
followed for group 3 patients, at the appropriate time for 
study III.

All recruited patients will be reviewed in Haematology 
outpatients at the respective hospitals, by pharmacists 
trained in the study.

Data collected for the purposes of the study will be re-
corded by the pharmacist on a pre-determined study 
form, which captures the information required for the 
study. At the earliest opportunity, the principal re-
searcher associated with the study will transfer the data 
to an excel database at the respective hospitals and sub-
sequently transfer to an SPSS database, with the hard 
copy of the data collection form being filed and stored 
in a locked office within the haematology department at 
King’s College Hospital, with only members of the clin-
ical team having access to this office.

One week after entry of a patient’s data onto the SPSS 
database, the data which had been entered will be re-
checked for any entry discrepancies by the principal 
researcher.

As soon as a patient consents to participate in the 
study, they will be given a unique study number. This 
number will be entered onto the SPSS database and will 
only be traceable back to an individual patient by accessing 
the study form for the patient in the haematology depart-
ment at King’s College Hospital.

All electronic data will be encrypted and password 
protected.

Only direct members of the research team will have 
access to the full set of electronic data generated within 
the study. The completed questionnaires for studies I, II 
and III will be stored within a locked office within the 
haematology department at King’s College Hospital.

Sample size and statistical analysis
Study I & II
Patients who are >75 % in TTR (group 1) will be classi-
ﬁed as adherent and those who are <50 % in TTR (group 
2) will be classiﬁed as non-adherent. To determine if pa-
tients’ beliefs about warfarin and their illness perception 
is associated with their adherence status, univariate ana-
lyses will ﬁrst be conducted to identify the key variables 
that will be entered into the multiple logistic regression 
model. Assuming a recruitment ratio of 1:1 of non-
adherent : adherent patients, a total sample size of 180 
to 240 patients will be able to accommodate 6 to 8 pre-
dictive variables. i.e. up to 120 patients who are adherent 
and up to 120 patients who are non-adherent are re-
quired as measured by TTR.

Multiple linear regression will be used to examine 
whether illness and treatment beliefs can predict adher-
ence to NOAC. Using the formula that 15 observations 
are needed per degree of freedom, a sample size of 240 
will be able to test whether illness and treatment beliefs 
(11 dimensions) and up to ﬁve demographic/clinical var-
iables can predict adherence to NOAC. Therefore a sam-
ple size of 240 patients who are switched to NOAC is 
required.

However, as the refusal rate for switching to NOAC 
for eligible patients is not known, and given that the 
NOAC patient sample will derive from those who are 
non-adherent to warfarin (<50 % TTR), at least 240 pa-
tients – rather than 120 patients - who are non-adherent 
will need to be recruited in order to be able to perform 
both the linear regression analysis and logistic regression 
analysis. A conservative refusal rate of 30 % would sug-
gest 342 patients who are <50 % TTR on warfarin would 
need to be recruited into group 2.

Study III
Three hundred forty-two patients will be recruited into 
group 2 which will act as the control group. Power 
calculations (GPower 3.1) assuming one-tailed analysis 
using an independent groups design, suggest that a 1:1 
matching i.e. recruiting 342 patients into the interven-
tion group (group 3) would allow for the detection of a 
small-sized effect of the intervention (d = 0.20).
The Switching study has been reviewed and given a favorable opinion by the London-Dulwich Research Ethics Committee: REC reference: 13/LO/1468.

Discussion
The Switching study aims to understand patient’s perception of their illness, their beliefs about medication and their anticoagulation specific quality of life, as it relates to adherence to anticoagulant therapy. We are not the first to study this in a population anticoagulated with VKA. Of particular note is the recently published TREAT study [42, 43]. This study was a randomised controlled trial of an intensive educational intervention for patients requiring VKA for stroke prevention in the context of AF. The study randomised warfarin-naïve patients to usual care and the intervention or usual care alone. The study administered the BMQ and IPQ-R [36, 37] to patients at baseline, 1, 2, 6 and 12 months post intervention, and found that a theory based educational intervention significantly improves TTR in patients during the first 6 months, although these benefits did not appear to be maintained longer-term. This study demonstrates the utility of validated psychometric instruments in understanding and designing interventions that improve anticoagulation control in patients, however the results also demonstrate that more work is needed to understand techniques that can support patients in maintaining effective levels of self-management, particularly with the use of NOAC therapy.

The availability of NOACs, has led to a drive in the UK to ensure that patients who would benefit from oral anticoagulation, are identified and offered appropriate treatment; this is particularly the case for stroke prevention in the context of AF. However, although these agents are easier to use, both from a clinician and patient perspective, the lack of formal clinic follow-up and re-enforcement of adherence could be a problem, given what is already known about non-adherence to medication for chronic conditions. Current cost-analysis which state that these NOACs are cost-effective [5–13], assume full adherence to medication. This is clearly not a true reflection of clinical practice. Therefore understanding patients views about their illness, their beliefs about the anticoagulant prescribed and their anticoagulation-related quality of life, should help us to understand what type of support patients prescribed both VKAs and NOAC long-term might require to support adherence. This should not only benefit the patient, it should help ensure commissioners obtain value for money, given the current and likely future financial constraints within the health service.

Our study began recruitment in July 2014 and the full results are expected in 3 years.

Additional files

Additional file 1: Questionnaire packs administered to patients prescribed warfarin. (PDF 276 kb)
Additional file 2: Questionnaire packs administered to patients prescribed apixaban. (PDF 276 kb)
Additional file 3: Questionnaire packs administered to patients prescribed dabigatran. (PDF 276 kb)
Additional file 4: Questionnaire packs administered to patients prescribed rivaroxaban*. (PDF 277 kb)

Abbreviations
ACTS, anti-clot treatment scale; BMQ, beliefs about medication questionnaire; CHA$_2$DS$_2$-VASc, congestive heart failure, hypertension, age ≥75 years (2), stroke (2), vascular disease, age 65–74 years, sex category (female (1)); CHADS$_2$S, congestive heart failure, hypertension, age ≥75 years, stroke (2); CIc, creatinine clearance; DVT, deep vein thrombosis; FBC, full blood count; GP, general practitioner; HASBLED, hypertension, abnormal renal or liver function, stroke, bleeding, labile INRs, elderly, drugs or alcohol; INR, International Normalised Ratio; IPQ, illness perceptions questionnaire; MRCI, medication related complexity index; NOAC, novel oral anticoagulant; PTS, post-thrombotic syndrome; SAMe-TT$_3$, sex (female); age (<60 years), medical history, treatment (interacting drugs), T (tobacco use within 2 years (2)), race (non-white (2)); TTR, time in therapeutic range; UEs, urea and electrolytes; VKA, Vitamin K antagonists

Acknowledgements
Not applicable.

Funding
The Switching study is funded by an investigator-initiated grant from Bayer Healthcare. The study funders had no role in study design and will not be involved in data collection or analysis.

Availability of data and materials
The questionnaire packs administered to patients are available as Additional files 1, 2, 3 and 4.

Authors’ contributions
JPP, VA and RA conceived the idea for the study, VA and JPP drafted the manuscript. BV, LB, AB, LNR, RKP, JKA and RA critically read and revised the manuscript. All authors read and approved the final manuscript.

Competing interests
VA, JPP, JKA, BV, LB, and AB have no competing interests. LNR has received speaker fees from Bayer and travel grants from Boehringer-Ingelheim. RKP has received speaker fees and sat on advisory boards for BMS/Pfizer, Bayer and Boehringer-Ingelheim. RA has received honoraria from Bayer, Pfizer and Boehringer-Ingelheim and research funding from Bayer.

Consent for publication
When consenting to the study, patients were made aware that the results from the study will be published in journals and at conferences.

Ethics approval and consent to participate
The Switching study has been reviewed and given a favorable opinion by the London-Dulwich Research Ethics Committee: REC reference: 13/LO/1468. All patients participating in the Switching study will provide written informed consent.

Author details
1King’s Thrombosis Centre, Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust, London, UK. 2Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King’s College London, 5th Floor, Franklin-Wilkins Building, London SE1 9NH, UK

Received: 3 October 2014 Accepted: 1 August 2016
Published online: 23 August 2016


References


